Antiretroviral agent | Cost (€) |
---|---|
FDCs | |
AtriplaTM (TDF / emtricitabine / efavirenz: 245 / 200 / 600 mg), 30 tablets | 701.08 |
CombivirTM (zidovudine / lamivudine: 300 / 150 mg), 60 tablets | 290.41 |
KaletraTM (lopinavir / ritonavir: 200 / 50 mg), 120 tablets | 400.02 |
KivexaTM (lamivudine / abacavir: 300 / 600 mg), 30 tablets | 355.54 |
TrizivirTM (zidovudine / lamivudine / abacavir: 300 / 150 / 300 mg), 60 tablets | 490.32 |
TruvadaTM (TDF / emtricitabine: 200 / 245 mg), 30 tablets | 432.73 |
Individual antiretroviral components of FDCs | |
Generic lamivudine (300 mg), 30 tablets | 62.76 |
SustivaTM (efavirenz: 600 mg), 30 tablets | 265.03 |
VireadTM (TDF: 250 mg), 30 tablets | 288.70 |
ZiagenTM (abacavir: 300 mg), 60 tablets | 225.69 |
Generic zidovudine (300 mg), 300 tablets | 403.15 |
Other antiretroviral agents employed in addition to FDCs | |
IntelenceTM (etravirine: 100 mg), 120 tablets | 450.00 |
IsentressTM (raltegravir: 400 mg), 60 tablets | 690.00 |
NorvirTM (ritonavir: 100 mg), 30 tablets | 22.46 |
PrezistaTM (darunavir: 400 mg), 60 tablets | 427.21 |
ReyatazTM (atazanavir: 200 mg), 60 tablets | 436.59 |
ReyatazTM (atazanavir: 300 mg), 30 tablets | 436.59 |
TelzirTM (fosamprenavir: 700 mg), 60 tablets | 316.89 |
ViramuneTM (nevirapine: 200 mg), 60 tablets | 199.69 |